用去纤苷可能会产生什么不良现象？

Defibrotide (defiteli) is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide can act on these receptors to produce a variety of downstream effects. Defibrotide can also reduce the expression of cell adhesion molecules on the surface of endothelial cells, thereby reducing the adhesion of leukocytes to vascular endothelial cells and reducing the inflammatory damage of endothelial cells.

In recent years, multiple clinical research results have shown that defibrotide (defiteli) is a safe and effective drug for preventing and treating HVOD after HSCT.

Richardson et al first explored its application in the treatment of HVOD after HSCT. In this trial, a total of 19 sHVOD patients participated in the treatment. Defibrinoside was administered at 5~60 mg/kg per day, intravenously infused, and the median usage time was 15 days (2-61 days). The results showed that 42% of patients achieved complete remission (CR), and the overall survival (os) rate 100 days after transplantation reached 32%. The effect is very obvious.

Drugs are three-part poisons. We all know that no matter which drug is used, it will produce varying degrees of adverse reactions after long-term use. Let’s take a look at the adverse phenomena that defibrinoside may cause.

The most common adverse events (incidence ≥10% and independent causal relationship) with treatment with defiteli are hypotension, diarrhea, vomiting, nausea, and epistaxis. Defibrinoside increases plasmin activity in vitro, and sputum may increase the risk of bleeding after hematopoietic stem cell transplantation (HSCT) in patients with VOD. Do not initiate defibrotide in patients with active bleeding. Hypersensitivity reactions have occurred in less than 2% of patients treated with defibrotide. These reactions include rash, urticaria, and angioedema.

The adverse phenomena caused by defibrotide often vary from person to person. If the patient feels that he or she has any abnormality, he or she should report it to your attending doctor in a timely manner.